P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma

• Hannah Moatti,
• Marie-Céleste Laroque,
• Loïc. Renaud,
• Odonchimeg Ravdan,
• Charlotte Schmidt-Hieber,
• Isabelle Madelaine,
• Roberta Di Blasi,
• Catherine Thieblemont,
• Pauline Brice

Affiliations

Hannah Moatti

1 Saint Louis Hospital, Hemato-Oncology

Marie-Céleste Laroque

2 Limoges Hospital

Loïc. Renaud

1 Saint Louis Hospital, Hemato-Oncology

Odonchimeg Ravdan

1 Saint Louis Hospital, Hemato-Oncology

Charlotte Schmidt-Hieber

1 Saint Louis Hospital, Hemato-Oncology

Isabelle Madelaine

3 Saint Louis Hospital, Pharmacy

Roberta Di Blasi

1 Saint Louis Hospital, Hemato-Oncology

Catherine Thieblemont

1 Saint Louis Hospital, Hemato-Oncology

Pauline Brice

1 Saint Louis Hospital, Hemato-Oncology